analyst-report:-solventum-corp

Analyst Report: Solventum Corp

Business

Argus

Aug 22, 2025

Solventum Corporation: Progress in transformation after spinout from 3M

Summary

Solvetum is a healthcare company that develops, manufactures, and commercializes a range of solutions. It has four business segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Solventum’s MedSurg segment provides advanced wound care and surgical solutions. Dental Solutions is a provider of a comprehensive suite of restorative, preventive, and orthodontic solutions for dentists and orthodontists. Health Information Systems (HIS) segment provides software solutions powered by clinical intelligence that create time for clinicians to care for patients and improve accuracy in healthcare reimbursement. Target customer markets include public and private hospitals, physician groups, and clinics, federal government agencies and payer organizations.

As noted earlier, Thermo Fisher has agreed to acquire the Purifi

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level

Upgrade

Analyst Profile

David H. Toung

Senior Analyst: Medical Devices & Healthcare Services

David covers the Pharmaceutical, Medical Devices, and Healthcare services sectors for Argus. He has more than two decades of experience in the financial analysis industry, having worked for McDonald & Co., JPMorgan Chase and Standard & Poor’s, among others. His commentary has appeared on CNBC and in The New York Times. Prior to his financial career, David was a private practice attorney in New Jersey, and served as a Judicial Clerk for an Appellate Division judge in the New Jersey Superior Court. David has a law degree from Rutgers University, where he was a member of the Law Review. He has a B.A. degree in Government from Cornell University. He has passed Level II of the Chartered Financial Analyst examination.